Healthcare Providers and Services
Company Overview of CBR Systems, Inc.
CBR Systems, Inc., also known as Cord Blood Registry Systems, operates a cord blood stem cell bank that serves families in the United States and internationally. The company focuses on advancing the clinical application of cord blood stem cells by partnering with research institutions. It offers collecting, processing, and long-term cryopreservation of newborn cord blood and tissue stem cell units that are contained in the umbilical cord blood of newborns. The company also creates collection devices designed for cord blood stem cells; and CellAdvantage, a collection kit that is designed to preserve and to help the safe delivery of the blood and/or tissue. CBR Systems, Inc. was formerly known...
1200 Bayhill Drive
San Bruno, CA 94066
Founded in 1992
Key Executives for CBR Systems, Inc.
Co-Founder and Executive Chairman
Co-Founder and Member of Scientific & Medical Advisory Board
Director of Corporate Communications
Compensation as of Fiscal Year 2014.
CBR Systems, Inc. Key Developments
CBR Systems, Inc. Presents at 2013 Stem Cell Meeting on the Mesa, Oct-14-2013 11:15 AM
Oct 8 13
CBR Systems, Inc. Presents at 2013 Stem Cell Meeting on the Mesa, Oct-14-2013 11:15 AM. Venue: Estancia La Jolla Hotel & Spa, La Jolla Ballroom AB, 9700 North Torrey Pines Road, La Jolla, CA 92037, United States.
CBR Systems, Inc. and Sutter Neuroscience Institute Launch First FDA-Approved Clinical Trial
Aug 21 12
Sutter Neuroscience Institute and CBR Systems, Inc. (CBR) are launching the first FDA-approved clinical trial to assess the use of a child's own cord blood stem cells to treat select patients with autism. This first-of-its-kind placebo controlled study will evaluate the ability of an infusion of cord blood stem cells to help improve language and behavior. The study is in conjunction with the Sutter Institute for Medical Research. According to the Centers for Disease Control and Prevention, autism spectrum disorders impact one in 88 children in the U.S., and one in 54 boys. The condition is thought to have multiple risk factors including genetic, environmental and immunological components. The study will enroll 30 children between the ages of two and seven, with a diagnosis of autism who meet the inclusion criteria for the study. Enrolled participants will receive two infusions-one of the child's own cord blood stem cells and one of a placebo-over the course of 13 months. Both the participants and the lead investigators will be blinded from knowing the content of each infusion. To ensure the highest quality and consistency in cord blood stem cell processing, storage and release for infusion, CBR is the only family stem cell bank providing units from clients for the study. A newborn's umbilical cord blood contains a unique population of stem cells that have been used for more than 20 years in medical practice to treat certain cancers, blood diseases and immune disorders. When patients undergo a stem cell transplant for these conditions, the stem cells effectively rebuild the blood and immune systems. The co-investigator of the study is Michael Carroll, M.D., medical director of the Blood and Marrow Transplantation and Hematological Malignancies Program at Sutter Medical Center, Sacramento.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries